Log in

NASDAQ:VIVE - Viveve Medical Stock Price, Forecast & News

$0.84
0.00 (0.00 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$0.83
Now: $0.84
$0.86
50-Day Range
$0.81
MA: $2.77
$5.56
52-Week Range
$0.79
Now: $0.84
$145.00
Volume269,339 shs
Average Volume1.91 million shs
Market Capitalization$1.24 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.06
Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable components. It markets its products through sales employees and distributors in the United States, the Asia Pacific, Europe, the Middle East, Latin America, and Canada. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VIVE
Previous SymbolOTCMKTS:PLCSD
CUSIPN/A
Phone720-696-8100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.52 million
Book Value$10.60 per share

Profitability

Net Income$-49,320,000.00
Net Margins-429.71%

Miscellaneous

Employees67
Market Cap$1.24 million
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable

Receive VIVE News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVE and its competitors with MarketBeat's FREE daily newsletter.


Viveve Medical (NASDAQ:VIVE) Frequently Asked Questions

What is Viveve Medical's stock symbol?

Viveve Medical trades on the NASDAQ under the ticker symbol "VIVE."

How were Viveve Medical's earnings last quarter?

Viveve Medical Inc (NASDAQ:VIVE) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($13.51) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($16.00) by $2.49. The firm had revenue of $1.05 million for the quarter. Viveve Medical had a negative net margin of 429.71% and a negative return on equity of 2,979.48%. View Viveve Medical's Earnings History.

When is Viveve Medical's next earnings date?

Viveve Medical is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Viveve Medical.

What price target have analysts set for VIVE?

6 analysts have issued twelve-month target prices for Viveve Medical's shares. Their forecasts range from $0.20 to $6.00. On average, they anticipate Viveve Medical's share price to reach $2.05 in the next twelve months. This suggests a possible upside of 144.6% from the stock's current price. View Analyst Price Targets for Viveve Medical.

What is the consensus analysts' recommendation for Viveve Medical?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viveve Medical in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Viveve Medical.

What are Wall Street analysts saying about Viveve Medical stock?

Here are some recent quotes from research analysts about Viveve Medical stock:
  • 1. Maxim Group analysts commented, "Yesterday, after the Market close, VIVE reported 2Q19 revenue inline with our estimates adjusted for the preannouncement on July 22, 2019, but lower than consensus." (8/9/2019)
  • 2. Mizuho analysts commented, "We expect these data readouts and milestone events will be the key drivers of VIVE shares in 2019/2020." (3/15/2019)

Has Viveve Medical been receiving favorable news coverage?

Media headlines about VIVE stock have been trending somewhat negative on Saturday, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Viveve Medical earned a news impact score of -1.8 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Viveve Medical.

Are investors shorting Viveve Medical?

Viveve Medical saw a increase in short interest during the month of November. As of November 29th, there was short interest totalling 353,600 shares, an increase of 176.5% from the November 14th total of 127,900 shares. Based on an average daily volume of 1,276,500 shares, the days-to-cover ratio is presently 0.3 days. Approximately 24.6% of the shares of the stock are short sold. View Viveve Medical's Current Options Chain.

Who are some of Viveve Medical's key competitors?

What other stocks do shareholders of Viveve Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viveve Medical investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Fortive (FTV), HP (HPQ), Lowe's Companies (LOW), Western Digital (WDC), Viking Therapeutics (VKTX), Quantenna Communications (QTNA), SCYNEXIS (SCYX) and Foundation Medicine (FMI).

Who are Viveve Medical's key executives?

Viveve Medical's management team includes the folowing people:
  • Mr. Scott C. Durbin, CEO & Director (Age 50)
  • Mr. James Gregory Atkinson, Chief Bus. Officer & Pres (Age 61)
  • Mr. Jim B. Robbins, VP of Fin. & Admin., Principal Accounting Officer and Principal Financial Officer (Age 55)
  • Ms. Deborah A. Jorn, Sr. Advisor to the CEO & Director (Age 61)
  • Mr. Martin Kerber, VP of Operations

When did Viveve Medical IPO?

(VIVE) raised $13 million in an initial public offering (IPO) on Tuesday, June 14th 2016. The company issued 1,600,000 shares at $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group acted as the underwriters for the IPO and Maxim Group was co-manager.

Who are Viveve Medical's major shareholders?

Viveve Medical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FNY Investment Advisers LLC (1.10%). View Institutional Ownership Trends for Viveve Medical.

Which institutional investors are buying Viveve Medical stock?

VIVE stock was bought by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. View Insider Buying and Selling for Viveve Medical.

How do I buy shares of Viveve Medical?

Shares of VIVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Viveve Medical's stock price today?

One share of VIVE stock can currently be purchased for approximately $0.84.

How big of a company is Viveve Medical?

Viveve Medical has a market capitalization of $1.24 million and generates $18.52 million in revenue each year. The company earns $-49,320,000.00 in net income (profit) each year or ($161.00) on an earnings per share basis. Viveve Medical employs 67 workers across the globe.View Additional Information About Viveve Medical.

What is Viveve Medical's official website?

The official website for Viveve Medical is http://www.viveve.com/.

How can I contact Viveve Medical?

Viveve Medical's mailing address is 345 INVERNESS DRIVE SOUTH BUILDING B SUITE 250, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-696-8100 or via email at [email protected]


MarketBeat Community Rating for Viveve Medical (NASDAQ VIVE)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  257 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  426
MarketBeat's community ratings are surveys of what our community members think about Viveve Medical and other stocks. Vote "Outperform" if you believe VIVE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel